Knowledge and pharmacological management of Alzheimer’s disease by managing community pharmacists: a nationwide study
- 433 Downloads
Background Managing community pharmacists can play a leading role in supporting community dwelling individuals with Alzheimer’s disease and their caregivers. Objective The main purpose of this study was to assess knowledge of managing community pharmacists towards Alzheimer’s disease and its pharmacological management. Setting Community pharmacies in the Maltese islands. Method A nationwide survey was conducted with full-time managing community pharmacists in possession of a tertiary education degree in pharmacy studies. The level of knowledge was investigated using the Alzheimer’s Disease Knowledge Scale and the Alzheimer’s Disease Pharmacotherapy Measure. Participants were also asked to rate a number of statements related to disease management. Results Maltese managing community pharmacists (57 % response rate) had inadequate knowledge on risk factors, caregiving issues and pharmacological management of Alzheimer’s disease. Age and number of years working in a community pharmacy setting were found to be negatively correlated with increased knowledge. Conclusion The findings highlight the need of providing training and continued educational support to managing community pharmacists in order to provide quality advice to individuals with dementia and their caregivers in the community.
KeywordsAlzheimer’s disease Dementia Knowledge Malta Maltese islands Managing community pharmacist Pharmacotherapy
The authors gratefully acknowledge all managing community pharmacists who participated in the study.
Conflicts of interest
The authors have no conflicts of interests.
- 3.Alzheimer’s Disease International. World Alzheimer Report 2015: The global impact of dementia. 2015. http://www.alz.co.uk/research/world-report-2015. Accessed 10 Mar 2016.
- 5.Scerri A, Scerri C. Dementia in Malta: new prevalence estimates and projected trends. Malta Med J. 2012;24:21–4.Google Scholar
- 6.Scerri C. Empowering change: a national strategy for dementia in the Maltese Islands. Valletta: Parliamentary Secretariat for the Rights of Persons with Disability and Active Ageing; 2015.Google Scholar
- 12.Cerejeira J, Lagarto L, Mukaetova-Ladinska EB. Behavioral and psychological symptoms of dementia. Front Neurol. 2012;7:73.Google Scholar
- 13.Medicines Act. 2003. http://www.justiceservices.gov.mt/DownloadDocument.aspx?app=lom&itemid=8924&l=1. Accessed 11 Mar 2016.
- 15.Polit DF, Beck CT. Essentials of nursing research: appraising evidence for nursing practice. 7th ed. Philadelphia: Lippincott; 2010.Google Scholar
- 23.National Institute of Clinical Excellence. Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease. 2011. https://www.nice.org.uk/guidance/ta217. Accessed 3 Mar 2016.
- 25.Banerjee S. The use of antipsychotic medication for people with dementia: time for action. 2009. http://www.rcpsych.ac.uk/pdf/Antipsychotic%20Bannerjee%20Report.pdf. Accessed 5 Mar 2016.